Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Cyclosporine in Beta-Thalassemia: NCT04009525 Clinical Landscape Report 2026
28 September 2026
NCT04009525 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Emeramide in Beta-Thalassemia: NCT04092205 Clinical Landscape Report 2026
28 September 2026
NCT04092205 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Luspatercept-AAMT in Beta-Thalassemia: NCT04143724 Clinical Landscape Report 2026
28 September 2026
NCT04143724 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Divesiran in Beta-Thalassemia: NCT04176653 Clinical Landscape Report 2026
28 September 2026
NCT04176653 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
β-globin restored autologous HSC(BRL Medicine Inc) in Beta-Thalassemia: NCT04205435 Clinical Landscape Report 2026
28 September 2026
NCT04205435 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sirolimus in Beta-Thalassemia: NCT04247750 Clinical Landscape Report 2026
28 September 2026
NCT04247750 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BRL-103 in Beta-Thalassemia: NCT04211480 Clinical Landscape Report 2026
28 September 2026
NCT04211480 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Exagamglogene Autotemcel in Beta-Thalassemia: NCT04208529 Clinical Landscape Report 2026
28 September 2026
NCT04208529 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acetylcysteine in Beta-Thalassemia: NCT04260516 Clinical Landscape Report 2026
28 September 2026
NCT04260516 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fanregratinib Tartrate in Mesothelioma, Malignant: NCT04290325 Clinical Landscape Report 2026
28 September 2026
NCT04290325 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
INCB-099318 in Endometrial Carcinoma: NCT04272034 Clinical Landscape Report 2026
28 September 2026
NCT04272034 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Malignant Pleural Mesothelioma: NCT04287829 Clinical Landscape Report 2026
28 September 2026
NCT04287829 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.